This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...

The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Esperion Therapeutics ESPR announced that it has come to an alignment with the FDA for initiating two phase III studies. The ...

The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium.  Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...

Lifespan is outpacing the number of years people live in good health. Scientists are developing ways of preventing illness and slowing the aging process ...

Investing.com -- Alnylam Pharmaceuticals (NASDAQ: NASDAQ: ALNY) stock climbed 5% as trading resumed on Friday morning, following the company’s announcement that the FDA has approved AMVUTTRA for ...

TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.